| abstract |
A compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein Y 'is O or S; W' is selected from the group consisting of and optionally substituted with one to four substituents selected from the group consisting of C 1-6 alkyl, aryl, N (R 7) 2, OR 7, N 3 , CN, C (O) R7, C1-3alkylenearyl, C1-3alkyleneN (R12) 2, and halo; Z 'is selected from the group consisting of: wherein: Q' is selected from the group consisting of hydrogen, OR7, SR7, and N (R7) 2, provided that Q 'is hydrogen when at least one of J', K ', L', and M 'represents N, O, or S; J' is selected from the group consisting of CR8, NR8, O , and S; iK 'is selected from the group consisting of CR9, NR9, O, and S; L 'is selected from the group consisting of CR10, NR10, O, and S; M 'is selected from the group consisting of CR11, NR11, O, and S, wherein: R7 is independently selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, cycloalkyl, aryl, heteroaryl, SO2R12, C1- 6alkyl substituted with one or more halo, hydroxy, aryl, heteroaryl, heterocycloalkyl, N (R 12) 2, and SO 2 R 12, C 1-3 alkylenearyl, C 1-3 alkyleneheteroaryl, C 1-3 alkyleneC 3-8 heterocycloalkyl, C 1-3 alkyleneSO 2 aryl, optionally R 3 alkyl substituted with C 1-3 alkylene ) 2, OCF3, C1-3alkyleneN (R12) 3+, C3-8heterocycloalkyl, and CH3 (C1-3alkyleneN (R12) 2) 2, or two R7 groups together form an optionally substituted 3- to 6-membered aliphatic ring; , R 9, and R 10 are each independently selected from the group consisting of: none, hydrogen, halo, optionally substituted C 1-6 alkyl, C 2-6 alkenyl, OCF 3, NO 2, CN, NC, N (R 7) 2, OR 7, CO2R 7 , C (O) N (R7) 2, C (O) R7, N (R13) COR7, N (R13) C (O) OR7, N (R7) C (O) OR7, N (R7) C (O) ) C 1-3 alkyleneC (O) R 7, N (R 7) C (O) C 1-3 alkyleneC (O) OR 7, N (R 7) C (O) C 1-3 alkyleneOR 7, N (R 7) C (O) C 1-3 alkyleneNHC (O) ) OR7, N (R7) C (O) C1-3alkyleneSO2NR7, CF3, C1-3alkyleneN (R12) SO2aryl, C1-3alk ilenN (R12) SO2heteroaryl, C1-3alkyleneOC1-3alkylenaryl, C1-3alkyleneN (R12) C1-3alkylenaryl, C1-3alkyleneN (R12) C1-3alkyleneheteroaryl, C1-3alkyleneN (R12) C (O) R7, C1-3alkyleneN C (O) C1-3alkyleneOR2, C1-3alkyleneN (R12) C (O) aryl, C1-3alkyleneN (R12) C (O) C1-3alkyleneN (R12) 2, C1-3alkyleneN (R12) C (O) heteroaryl, C1-3alkyleneOR7, and SR7, wherein R7 is as previously defined, R11 is selected from the group consisting of none, hydrogen, optionally substituted C1-6alkyl, and halo, R12 is selected from the group consisting of odonik, C1-6alkyl, cycloalkyl, aryl, heteroaryl, C1-3alkylenearyl, and SO2 C1-6alkyl, or two R12 groups together form an optionally substituted 3- to 6-membered ring; iR13 is selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-66alkynyl, and aryl, provided that when Q 'is hydrogen or OCH3, at least one of R8, R9, and R10 is different from hydrogen, CH3 , OCH3, and halo, provided that the compound is not N- $ 6- (benzylpyrid-2-yl)] - N '- (2-pyrazinyl) thiourea. The application contains 15 more claims. |